Hide

FocusBar

Subscribe to Premium Member
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.454
SYK's Cash to Debt is ranked lower than
469483% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 6.22 vs. SYK: 2.454 )
SYK' s 10-Year Cash to Debt Range
Min: 0.05   Max: 164.16
Current: 2.45

0.05
164.16
Equity to Asset 0.381
SYK's Equity to Asset is ranked lower than
518134% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 0.58 vs. SYK: 0.381 )
SYK' s 10-Year Equity to Asset Range
Min: -0.09   Max: 0.61
Current: 0.38

-0.09
0.61
F-Score: 5
Z-Score: 5.07
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 20.10
SYK's Operating margin (%) is ranked higher than
77% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 10.20 vs. SYK: 20.10 )
SYK' s 10-Year Operating margin (%) Range
Min: -5.6   Max: 23.9
Current: 20.1

-5.6
23.9
Net-margin (%) 15
SYK's Net-margin (%) is ranked higher than
75% of the 145 Companies
in the Global Medical Devices industry.

( Industry Median: 7.90 vs. SYK: 15 )
SYK' s 10-Year Net-margin (%) Range
Min: 0.9   Max: 17.4
Current: 15

0.9
17.4
ROE (%) 15.1
SYK's ROE (%) is ranked higher than
77% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. SYK: 15.1 )
SYK' s 10-Year ROE (%) Range
Min: 2.9   Max: 25.9
Current: 15.1

2.9
25.9
ROA (%) 9.8
SYK's ROA (%) is ranked higher than
73% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 5.90 vs. SYK: 9.8 )
SYK' s 10-Year ROA (%) Range
Min: 0.8   Max: 15.1
Current: 9.8

0.8
15.1
ROC (Joel Greenblatt) (%) 59.30
SYK's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 23.90 vs. SYK: 59.30 )
SYK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13.8   Max: 70.9
Current: 59.3

-13.8
70.9
Revenue Growth (%) 7.6
SYK's Revenue Growth (%) is ranked higher than
54% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. SYK: 7.6 )
SYK' s 10-Year Revenue Growth (%) Range
Min: 6.2   Max: 12.9
Current: 7.6

6.2
12.9
EBITDA Growth (%) 1.5
SYK's EBITDA Growth (%) is ranked lower than
94% of the 63 Companies
in the Global Medical Devices industry.

( Industry Median: 8.70 vs. SYK: 1.5 )
SYK' s 10-Year EBITDA Growth (%) Range
Min: 1.5   Max: 101.1
Current: 1.5

1.5
101.1
EPS Growth (%) 5.2
SYK's EPS Growth (%) is ranked lower than
1923075% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 11.60 vs. SYK: 5.2 )
SYK' s 10-Year EPS Growth (%) Range
Min: 5.2   Max: 103.1
Current: 5.2

5.2
103.1
» SYK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

SYK Guru Trades in Q2 2012

Chuck Royce 45,485 sh (+56.14%)
PRIMECAP Management 304,500 sh (+24.11%)
Ken Fisher 8,656 sh (+0.65%)
Donald Yacktman 5,588,299 sh (+0.37%)
John Hussman 500,000 sh (unchged)
Robert Olstein 145,000 sh (unchged)
Murray Stahl 5,500 sh (unchged)
Paul Tudor Jones 43,400 sh (-3.98%)
Pioneer Investments 960,734 sh (-7.58%)
Jeremy Grantham 518,792 sh (-8.34%)
Mario Gabelli 9,275 sh (-48.1%)
Joel Greenblatt 9,114 sh (-59.17%)
Ray Dalio 7,819 sh (-84.49%)
Jim Simons 55,200 sh (-86.29%)
Steven Cohen 61,973 sh (-89.52%)
» More
Q3 2012

SYK Guru Trades in Q3 2012

Joel Greenblatt 76,455 sh (+738.87%)
Ray Dalio 54,706 sh (+599.65%)
Donald Yacktman 9,720,600 sh (+73.95%)
Chuck Royce 55,625 sh (+22.29%)
Murray Stahl 5,639 sh (+2.53%)
Robert Olstein 145,000 sh (unchged)
Yacktman Focused Fund 4,457,523 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Yacktman Fund 3,900,000 sh (unchged)
Pioneer Investments Sold Out
Jim Simons Sold Out
John Hussman Sold Out
Mario Gabelli Sold Out
Ken Fisher 8,586 sh (-0.81%)
Jeremy Grantham 505,092 sh (-2.64%)
Steven Cohen 20,476 sh (-66.96%)
Paul Tudor Jones 10,400 sh (-76.04%)
» More
Q4 2012

SYK Guru Trades in Q4 2012

Jim Simons 302,300 sh (New)
George Soros 75,000 sh (New)
Ray Dalio 78,006 sh (+42.59%)
Chuck Royce 72,890 sh (+31.04%)
Yacktman Fund 4,900,000 sh (+25.64%)
Donald Yacktman 12,064,853 sh (+24.12%)
Yacktman Focused Fund 5,100,000 sh (+14.41%)
Jeremy Grantham 448,264 sh (unchged)
PRIMECAP Management 304,500 sh (unchged)
Murray Stahl Sold Out
Ken Fisher 8,395 sh (-2.22%)
Steven Cohen 19,904 sh (-2.79%)
Robert Olstein 139,000 sh (-4.14%)
Joel Greenblatt 64,239 sh (-15.98%)
Paul Tudor Jones 6,300 sh (-39.42%)
» More
Q1 2013

SYK Guru Trades in Q1 2013

Vanguard Health Care Fund 1,433,500 sh (New)
Jeremy Grantham 922,064 sh (+105.7%)
Joel Greenblatt 73,682 sh (+14.7%)
Chuck Royce 82,600 sh (+13.32%)
Paul Tudor Jones 6,800 sh (+7.94%)
Donald Yacktman 12,069,183 sh (+0.04%)
PRIMECAP Management 304,500 sh (unchged)
Yacktman Focused Fund 5,100,000 sh (unchged)
Yacktman Fund 4,900,000 sh (unchged)
George Soros Sold Out
Steven Cohen Sold Out
Ken Fisher 8,000 sh (-4.71%)
Robert Olstein 108,000 sh (-22.3%)
Ray Dalio 6,552 sh (-91.6%)
Jim Simons 7,300 sh (-97.59%)
» More
» Details

Insider Trades

Latest Guru Trades with SYK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-03-31 New Buy0.37%$54.82 - $66.81 $ 67.247%1433500
George Soros 2013-03-31 Sold Out 0.05%$54.82 - $66.81 $ 67.247%0
Ray Dalio 2013-03-31 Reduce -91.6%0.04%$54.82 - $66.81 $ 67.247%6552
Donald Yacktman 2012-12-31 Add 24.12%0.78%$52 - $56.57 $ 67.2425%12064853
Yacktman Fund 2012-12-31 Add 25.64%0.76%$52 - $56.57 $ 67.2425%4900000
Yacktman Focused Fund 2012-12-31 Add 14.41%0.55%$52 - $56.57 $ 67.2425%5100000
George Soros 2012-12-31 New Buy0.05%$52 - $56.57 $ 67.2425%75000
Ray Dalio 2012-12-31 Add 42.59%0.01%$52 - $56.57 $ 67.2425%78006
Donald Yacktman 2012-09-30 Add 73.95%1.4%$50.74 - $56.21 $ 67.2426%9720600
John Hussman 2012-09-30 Sold Out 0.52%$50.74 - $56.21 $ 67.2426%0
Joel Greenblatt 2012-09-30 Add 738.87%0.25%$50.74 - $56.21 $ 67.2426%76455
Ray Dalio 2012-09-30 Add 599.65%0.04%$50.74 - $56.21 $ 67.2426%54706
Mario Gabelli 2012-09-30 Sold Out 0.0038%$50.74 - $56.21 $ 67.2426%0
Joel Greenblatt 2012-06-30 Reduce -59.17%0.07%$49.7 - $55.99 $ 67.2426%9114
Ray Dalio 2012-06-30 Reduce -84.49%0.04%$49.7 - $55.99 $ 67.2426%7819
PRIMECAP Management 2012-06-30 Add 24.11%0.01%$49.7 - $55.99 $ 67.2426%304500
Mario Gabelli 2012-06-30 Reduce -48.1%$49.7 - $55.99 $ 67.2426%9275
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Stryker Corporation

Yacktman Fund Buys Dell Inc, Stryker Corporation, Coca-cola Co, Sells H&R Block Inc, Research In Motion Ltd, Liberty Ventures Yacktman Fund - Yacktman Fund Buys Dell Inc, Stryker Corporation, Coca-cola Co, Sells H&R Block Inc, Research In Motion Ltd, Liberty Ventures
Besides the 13F of Yacktman Asset Management and Yacktman Focused Fund, we also started to track the portfolio of Yacktman Fund. Yacktman Fund is the flagship fund of Don Yacktman. The fund has achieved 10.6% of annual return over the past 10 years. It heavily invests in high quality large caps. As of Dec. 31, the fund has 51% of asset in top 10 positions and 16% in cash. Read more...
Donald Yacktman Finds Two Undervalued Companies in His Most Bought, In-Favor Sector of Q3 Donald Yacktman - Donald Yacktman Finds Two Undervalued Companies In His Most Bought, In-Favor Sector Of Q3
Donald Yacktman is an expert at identifying out-of-favor or undervalued sectors, buying them at the right price and ultimately profiting from their resurgence. “We use a variety of techniques to find ideas, including screens, although the best opportunities are often created because of short-term challenges within a business or its sector,” he said recently. Read more...
Weekly Top Insider Sells: GOOG, SYK, TDG, CIE, EW
According to GuruFocus Insider Data, these are the largest insider sells during the past week. The overall trend of insiders is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.60
SYK's P/E(ttm) is ranked lower than
675675% of the 148 Companies
in the Global Medical Devices industry.

( Industry Median: 23.60 vs. SYK: 20.60 )
SYK' s 10-Year P/E(ttm) Range
Min: 11.3   Max: 80.46
Current: 20.6

11.3
80.46
P/B 3.00
SYK's P/B is ranked lower than
490196% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. SYK: 3.00 )
SYK' s 10-Year P/B Range
Min: 2.21   Max: 13.5
Current: 3

2.21
13.5
P/S 2.90
SYK's P/S is ranked lower than
465116% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. SYK: 2.90 )
SYK' s 10-Year P/S Range
Min: 1.93   Max: 5.76
Current: 2.9

1.93
5.76
PFCF 15.70
SYK's PFCF is ranked lower than
813007% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 20.43 vs. SYK: 15.70 )
SYK' s 10-Year PFCF Range
Min: 11.63   Max: 62.01
Current: 15.7

11.63
62.01
EV-to-EBIT 14.5
SYK's EV-to-EBIT is ranked lower than
558659% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 19.60 vs. SYK: 14.5 )
SYK' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 181.4
Current: 14.5

6.8
181.4
PEG 5.3
SYK's PEG is ranked lower than
2173911% of the 46 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. SYK: 5.3 )
SYK' s 10-Year PEG Range
Min: 0.58   Max: 5.3
Current: 5.3

0.58
5.3
Shiller P/E 20.9
SYK's Shiller P/E is ranked lower than
100% of the Companies
in the Global Medical Devices industry.

( Industry Median: vs. SYK: 20.9 )
SYK' s 10-Year Shiller P/E Range
Min: 15.77   Max: 79.73
Current: 20.9

15.77
79.73

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.40
SYK's Dividend Yield is ranked lower than
1063829% of the 94 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. SYK: 1.40 )
SYK' s 10-Year Dividend Yield Range
Min: 0.13   Max: 1.66
Current: 1.4

0.13
1.66
Dividend Payout 0.292
SYK's Dividend Payout is ranked lower than
1449274% of the 69 Companies
in the Global Medical Devices industry.

( Industry Median: 0.40 vs. SYK: 0.292 )
SYK' s 10-Year Dividend Payout Range
Min: 0.05   Max: 0.66
Current: 0.29

0.05
0.66
Dividend growth (3y) 56.6
SYK's Dividend growth (3y) is ranked higher than
92% of the 13 Companies
in the Global Medical Devices industry.

( Industry Median: 10.30 vs. SYK: 56.6 )
SYK' s 10-Year Dividend growth (3y) Range
Min: -9.1   Max: 56.6
Current: 56.6

-9.1
56.6
Yield on cost (5-Year) 7.08
SYK's Yield on cost (5-Year) is ranked lower than
1052631% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. SYK: 7.08 )
SYK' s 10-Year Yield on cost (5-Year) Range
Min: 0.66   Max: 8.4
Current: 7.08

0.66
8.4
Share Buyback Rate 1
SYK's Share Buyback Rate is ranked lower than
2702700% of the 37 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. SYK: 1 )
SYK' s 10-Year Share Buyback Rate Range
Min: 1.5   Max: -1.2
Current: 1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 15
SYK's Price/Net Current Asset Value is ranked lower than
523560% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 13.00 vs. SYK: 15 )
SYK' s 10-Year Price/Net Current Asset Value Range
Min: 11.4   Max: 28.5
Current: 15

11.4
28.5
Price/Tangible Book 5.1
SYK's Price/Tangible Book is ranked lower than
520833% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. SYK: 5.1 )
SYK' s 10-Year Price/Tangible Book Range
Min: 3.7   Max: 632.4
Current: 5.1

3.7
632.4
Price/DCF (Projected) 1.3
SYK's Price/DCF (Projected) is ranked lower than
1369862% of the 73 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. SYK: 1.3 )
SYK' s 10-Year Price/DCF (Projected) Range
Min: 0.9   Max: 9.3
Current: 1.3

0.9
9.3
Price/Median PS Value 0.7
SYK's Price/Median PS Value is ranked lower than
510204% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. SYK: 0.7 )
SYK' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 1.3
Current: 0.7

0.6
1.3
Price/Graham Number 2.1
SYK's Price/Graham Number is ranked lower than
699300% of the 143 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. SYK: 2.1 )
SYK' s 10-Year Price/Graham Number Range
Min: 1.5   Max: 36.7
Current: 2.1

1.5
36.7
Earnings Yield (Greenblatt) 6.90
SYK's Earnings Yield (Greenblatt) is ranked higher than
68% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. SYK: 6.90 )
SYK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 14.6
Current: 6.9

0.6
14.6
Forward Rate of Return (Yacktman) 7.6
SYK's Forward Rate of Return (Yacktman) is ranked lower than
1666665% of the 60 Companies
in the Global Medical Devices industry.

( Industry Median: 7.85 vs. SYK: 7.6 )
SYK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.8   Max: 43.8
Current: 7.6

-0.8
43.8

Business Description

Stryker Corporation was incorporated in Michigan in 1946 as the successor company to a business founded in 1941. It is a medical technology company. The Company's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties. The Company's three reportable business segments are Reconstructive, MedSurg, and Neurotechnology and Spine. The Reconstructive segment includes orthopaedic reconstructive (hip and knee) and trauma implant systems as well as other related products. The MedSurg segment include surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); reprocessed and remanufactured medical devices; as well as other medical device products used in a variety of medical specialties.. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company's neurotechnology offering includes products used for minimally invasive endovascular techniques, as well as a comprehensive line of products for traditional brain and open skull base surgical procedures, orthobiologic and biosurgery products including synthetic bone grafts and vertebral augmentation products, as well as minimally invasive products for the treatment of acute ischemic stroke. The Company also develops, manufactures and markets spinal implant products including cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies. In the United States, most of the Company's products are marketed directly to doctors, hospitals and other health-care facilities. The Company's main competitors in neurotechnology are Covidien and Micrus Endovascular, LLC and in spine products are Medtronic Sofamor Danek, Inc., DePuy Spine, Inc. and Synthes, Inc. The Company's businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SMA, ZMH, STJ, EW
Traded in other countries:SYK.Germany

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial